PerkinElmer realigns business for strategic focus
This article was originally published in Clinica
Executive Summary
Life sciences group PerkinElmer is set to re-organise its business operations into two segments – human health and environmental health – in order to make its strategic mission clearer and improve its communication. As of January 1 2009, the company’s human health business will specialise in developing diagnostics, tools and applications to fight illness, provide better medical insight, and create new therapies. This unit will incorporate Waltham, Massachusetts-based PerkinElmer’s genetic screening, bio-discovery and medical imaging operations and will be led by the firm’s president and CEO Robert Friel on an interim basis. The environmental health side of the business will house the company’s analytical sciences, laboratory services and detection and illumination units and will be headed by John Roush, who is currently head of its optoelectronics arm.
You may also be interested in...
Alere aided by professional diagnostics sales in fourth quarter
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra and Stout to work on expandable interbody device
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals